Expanding the horizon for Refractory and Relapsing Chronic Lymphocytic Leukaemia and Follicular Lymphoma - Certificate of Completion

Duration

1.5 hrs

Profession

Specialist

# of Credits

1.5

Accreditation

Certificate of Completion

Expiry Date

2020-09-11

Treatment of Chronic Lymphocytic Leukaemia and Follicular Lymphoma has undergone significant evolution over the last decade with the advent of rituximab. Since then, a new class of targeted therapies has been developed which offers the possibility of a paradigm shift in this disease, with greater effectiveness in prolongation of progression-free survival compared to standard therapies.

This interactive online learning activity is valued at 1.5 Hour(s) of continuing education. Fellows of The Royal Australasian College of Physicians (RACP) can claim CPD credits in MyCPD for participation in this course. www.racp.edu.au/mycpd (log in to MyCPD).

Chan Yoon Cheah
MBBS, FRACP, FRCPA, DMedSc
Clinical Senior Lecturer, University of Western Australia
Consultant Haematologist,
Sir Charles Gairdner Hospital, Perth, WA

Professor Maher Gandhi
MBChB, PhD, FRCP, FRACP, FRCPath,
LF Chair in Blood Cancer Research,
The University of Queensland Diamantina Institute,
Haematology Specialist,
Princess Alexandra Hospital, Brisbane, QLD

À la fin de ce programme, le participant sera en mesure de :

  • décrire comment les résultats cardiovasculaires obtenus lors d’études ont contribué aux changements apportés à l’algorithme de traitement de Diabète Canada pour le diabète de type 2;
  • analyser les bienfaits et les risques des traitements antihyperglycémiants qui ont démontré des bienfaits cardiovasculaires en traitement de deuxième intention du diabète de type 2;
  • conseiller les patients atteints d’un diabète de type 2 pour appuyer la protection vasculaire en milieu pharmaceutique.


Related Courses